NicOx, Ferrer select NCX 1047 as candidate for development in dermatology collaboration

By Lisa Kerner

Erie, Pa., May 16 - NicOx SA and Grupo Ferrer Internacional, SA have selected NCX 1047 as the development candidate in their dermatology collaboration, marking the successful completion of the partners' research program, according to a company news release.

The goal of the collaboration, announced in September 2005, was to identify a new synthetic nitric oxide (NO)-donating corticosteroid with the potential for an improved risk-benefit ratio over the commonly prescribed corticosteroids associated with local side effects.

A number of NO-donating compounds were synthesized and assessed during the research program. Compounds that passed a first round were assessed in several different in vivo models of skin inflammation and specific dermatological disorders, NicOx said.

NCX 1047 was chosen because of its superior overall profile.

"We believe there is a clear market need for a higher potency corticosteroid with improved local safety and tolerability, or which could be used more sparingly due to increased activity," NicOx vice president of research Ennio Ongini said in the release.

"Both partners are eager to complete preclinical development of NCX 1047 and initiate clinical development as soon as possible."

Located in Sophia-Antipolis, France, NicOx develops nitric oxide-donating drugs for pain and inflammation and cardio-metabolic disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.